Vyvanse gains indication for ADHD in adolescents
The FDA has approved Vyvanse (lisdexamfetamine dimesylate capsules, from Shire) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents 13-17 years of age.
Diagnosis & Disease Information
Kapvay approved for ADHD
The FDA has approved Kapvay (clonidine HCl extended-release tablets, from Shionogi) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents ages 6-17 years old.
Daytrana gains indication for attention deficit hyperactivity disorder (ADHD) in adolescents
The FDA has approved Daytrana (methylphenidate transdermal system, from Shire) for the treatment of attention deficit hyperactivity disorder (ADHD) in adolescents 13-17 years of age.
CDC issues statement and recommendations regarding prescription drug misuse
The CDC announced the 2009 National Youth Risk Behavior Survey (YRBS) found that 1 in 5 high school students have ever taken a prescription drug such as OxyContin (oxycodone, from Purdue), Percocet (oxycodone/acetaminophen, from Endo), Vicodin (hydrocodone/acetaminophen, from Abbott), Adderall (mixed salts of a single-entity amphetamine product, from Shire), Ritalin (methylphenidate, from Novartis), or Xanax (alprazolam, from Pfizer), without a prescription.
